These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 22459310)

  • 1. Relation of improvement in estimated glomerular filtration rate with atorvastatin to reductions in hospitalizations for heart failure (from the Treating to New Targets [TNT] study).
    Ho JE; Waters DD; Kean A; Wilson DJ; Demicco DA; Breazna A; Wun CC; Deedwania PC; Khush KK;
    Am J Cardiol; 2012 Jun; 109(12):1761-6. PubMed ID: 22459310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.
    Koren MJ; Davidson MH; Wilson DJ; Fayyad RS; Zuckerman A; Reed DP;
    Am J Kidney Dis; 2009 May; 53(5):741-50. PubMed ID: 19216014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of high-dose atorvastatin on renal function in subjects with stroke or transient ischemic attack in the SPARCL trial.
    Amarenco P; Callahan A; Campese VM; Goldstein LB; Hennerici MG; Messig M; Sillesen H; Welch KM; Wilson DJ; Zivin JA
    Stroke; 2014 Oct; 45(10):2974-82. PubMed ID: 25147328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study.
    Shepherd J; Kastelein JJ; Bittner V; Deedwania P; Breazna A; Dobson S; Wilson DJ; Zuckerman A; Wenger NK;
    J Am Coll Cardiol; 2008 Apr; 51(15):1448-54. PubMed ID: 18402899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effect of atorvastatin (80 mg) versus simvastatin (20 to 40 mg) in preventing hospitalizations for heart failure in patients with previous myocardial infarction.
    Strandberg TE; Holme I; Faergeman O; Kastelein JJ; Lindahl C; Larsen ML; Olsson AG; Pedersen TR; Tikkanen MJ;
    Am J Cardiol; 2009 May; 103(10):1381-5. PubMed ID: 19427432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS).
    Colhoun HM; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Livingstone SJ; Charlton-Menys V; DeMicco DA; Fuller JH;
    Am J Kidney Dis; 2009 Nov; 54(5):810-9. PubMed ID: 19540640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study.
    Khush KK; Waters DD; Bittner V; Deedwania PC; Kastelein JJ; Lewis SJ; Wenger NK
    Circulation; 2007 Feb; 115(5):576-83. PubMed ID: 17261662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relation Between Change in Renal Function and Cardiovascular Outcomes in Atorvastatin-Treated Patients (from the Treating to New Targets [TNT] Study).
    Shepherd J; Breazna A; Deedwania PC; LaRosa JC; Wenger NK; Messig M; Wilson DJ;
    Am J Cardiol; 2016 Apr; 117(8):1199-205. PubMed ID: 26940556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progression of Renal Impairment and Chronic Kidney Disease in Chronic Heart Failure: An Analysis From GISSI-HF.
    Damman K; Masson S; Lucci D; Gorini M; Urso R; Maggioni AP; Tavazzi L; Tarantini L; Tognoni G; Voors A; Latini R
    J Card Fail; 2017 Jan; 23(1):2-9. PubMed ID: 27638233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study.
    Shepherd J; Kastelein JJ; Bittner V; Deedwania P; Breazna A; Dobson S; Wilson DJ; Zuckerman A; Wenger NK;
    Clin J Am Soc Nephrol; 2007 Nov; 2(6):1131-9. PubMed ID: 17942759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of cardiovascular events in statin-treated stable coronary patients by lipid and nonlipid biomarkers.
    Arsenault BJ; Barter P; DeMicco DA; Bao W; Preston GM; LaRosa JC; Grundy SM; Deedwania P; Greten H; Wenger NK; Shepherd J; Waters DD; Kastelein JJ;
    J Am Coll Cardiol; 2011 Jan; 57(1):63-9. PubMed ID: 21185503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beneficial effects of aggressive low-density lipoprotein cholesterol lowering in women with stable coronary heart disease in the Treating to New Targets (TNT) study.
    Wenger NK; Lewis SJ; Welty FK; Herrington DM; Bittner V;
    Heart; 2008 Apr; 94(4):434-9. PubMed ID: 18070940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship of High-Density Lipoprotein Cholesterol With Renal Function in Patients Treated With Atorvastatin.
    Ong KL; Waters DD; Fayyad R; Vogt L; Melamed S; DeMicco DA; Rye KA; Barter PJ
    J Am Heart Assoc; 2018 Jan; 7(2):. PubMed ID: 29358194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atorvastatin treatment improves endothelial function through endothelial progenitor cells mobilization in ischemic heart failure patients.
    Oikonomou E; Siasos G; Zaromitidou M; Hatzis G; Mourouzis K; Chrysohoou C; Zisimos K; Mazaris S; Tourikis P; Athanasiou D; Stefanadis C; Papavassiliou AG; Tousoulis D
    Atherosclerosis; 2015 Feb; 238(2):159-64. PubMed ID: 25525743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study).
    LaRosa JC; Grundy SM; Kastelein JJ; Kostis JB; Greten H;
    Am J Cardiol; 2007 Sep; 100(5):747-52. PubMed ID: 17719314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of atorvastatin on kidney function in chronic kidney disease: a randomised double-blind placebo-controlled trial.
    Fassett RG; Robertson IK; Ball MJ; Geraghty DP; Coombes JS
    Atherosclerosis; 2010 Nov; 213(1):218-24. PubMed ID: 20810109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship of oxidized phospholipids on apolipoprotein B-100 to cardiovascular outcomes in patients treated with intensive versus moderate atorvastatin therapy: the TNT trial.
    Byun YS; Lee JH; Arsenault BJ; Yang X; Bao W; DeMicco D; Laskey R; Witztum JL; Tsimikas S;
    J Am Coll Cardiol; 2015 Apr; 65(13):1286-1295. PubMed ID: 25835440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: rationale and design of the ASsessment of clinical Usefulness in CKD patients with Atorvastatin (ASUCA) trial.
    Ueshima K; Kasahara M; Koya D; Babazono T; Sato T; Imamoto M; Yasuno S; Fujimoto A; Tanaka S; Kimura G; Nakao K
    Clin Exp Nephrol; 2013 Apr; 17(2):211-7. PubMed ID: 22948416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relation of improvement in glomerular filtration rate with atorvastatin to reductions in heart failure morbidity.
    Athyros VG; Karagiannis A; Katsiki N; Mikhailidis DP
    Am J Cardiol; 2012 Sep; 110(5):763. PubMed ID: 22883077
    [No Abstract]   [Full Text] [Related]  

  • 20. The impact of pre-intervention rate of kidney function change on the assessment of CKD progression.
    Fassett RG; Geraghty DP; Coombes JS
    J Nephrol; 2014 Oct; 27(5):515-9. PubMed ID: 24504906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.